BusinessAdamas to Host Investor and Analyst Meeting on September 18, 2017By Nasdaq OMXSep 13, 2017, 8:53 PM UTC
BusinessAdamas Announces FDA Approval of GOCOVRI™ as First and Only Medication for the Treatment of Dyskinesia in Parkinson’s Disease PatientsBy Nasdaq OMXAug 24, 2017, 8:16 PM UTC
BusinessAdamas Reports Recent Achievements and Second Quarter 2017 Financial ResultsBy Nasdaq OMXAug 8, 2017, 8:01 PM UTC
BusinessAdamas to Announce First Quarter 2017 Financial Results and Host Conference Call on May 9, 2017By Nasdaq OMXMay 2, 2017, 8:08 PM UTC
BusinessAdamas Presents ADS-5102 Pooled Phase 3 Data Confirming Statistically Significant Reduction in Levodopa-Induced Dyskinesia and OFF Time in People with Parkinson’s DiseaseBy Nasdaq OMXApr 24, 2017, 1:06 PM UTC
BusinessAdamas Announces Oral and Poster Presentations of ADS-5102 Pooled Phase 3 Data at the 69th American Academy of Neurology Annual MeetingBy Nasdaq OMXApr 18, 2017, 4:08 PM UTC
